FXN and hypertrophic cardiomyopathy: This alteration leads to a partial silencing of transcription of frataxin (FXN), its encoded protein, causing a multisystem disorder disease that includes neurological damage, mainly spinocerebellar ataxia, and non-neurological signs such as hypertrophic cardiomyopathy and diabetes Mellitus type 2.